04.05.2020 – IGEA Pharma N.V.

IGEA to partner with Acalis for Alz1 wholesale distribution in the US

IGEA Pharma N.V. / Key word(s): Miscellaneous
IGEA to partner with Acalis for Alz1 wholesale distribution in the US

04-May-2020 / 03:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


IGEA to partner with Acalis for Alz1 wholesale distribution in the US

Hoofddorp, the Netherlands, 4 May 2020. IGEA Pharma N.V. (SIX: IGPH) today
announced a further extension of the partnership with Acalis by signing an
agreement for the wholesale distribution of the Alzheimer's prevention kit
'Alz1' in the US.

IGEA and Acalis started to partner on a commercial basis beginning 2020 for
exclusive distribution in Middle East and some European and South American
countries, including Belgium, Chile, Colombia, Uruguay and Peru, of IGEA's
products and solutions. The partnership extends now to the US, where yearly
500'000 people over 65 develop Alzheimer (which is someone every 65
seconds), 5.6 million people over 65 has Alzheimer and 16 million people
daily take care about them.

IGEA will continue to distribute Alz1 on its e-commerce platform, and
together with this new license agreement, IGEA expects to strengthen the
market position of Alz1 with a substantial impact on its net revenues.

Under the terms of the agreement, the commercialization of Alz1 on a
wholesale basis is expected to start within the next six months. In addition
to supplying Alz1, IGEA will also provide certain services to Acalis
including lab testing and data management and get an expected double-digit
license fee determined pursuant to a shared risk-reward concept.

Acalis is an international healthcare group whose goal is to maximize the
standards of comfort in care around the world. Acalis and AcalisCare are
brands that today represent a seal of quality in the field of global elderly
care, home care, rehabilitation, and post-hospital support with more than 40
centers, over 3,000 beds and more than 2,600 employees. As such, Acalis is
one of the most global private home care and assistance providers in Europe,
Latin America and Middle East, in particular Saudi Arabia and Turkey, and is
expanding in Asia and North America


About IGEA
IGEA Pharma focuses on health-tech and med-tech products and devices.
Health-tech products are exclusively preventative. IGEA commercializes an
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit
to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary
supplement designed to reduce blood heavy metals content), and expects to
launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound
copper is an expected Alzheimer's and diabetes type II associated biomarker.
Determining and regulating non-bound copper can contribute to reduce the
risk of Alzheimer's and diabetes type II. Med-tech products focuses on
selected solutions and specialities. IGEA operates in air and inanimate
environmental surface sanitization with aerosol technology-based devices and
expects to start commercializing polymeric based medical bags and other
specialty devices for medical use during 2020.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.com

This document constitutes neither an offer to buy nor to subscribe
securities and neither this document nor any part of it should form the
basis of any investment decision in IGEA.

The information contained in this press release has been carefully prepared.
However, IGEA bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. IGEA does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This publication may contain specific forward-looking statements and
assessments or intentions concerning IGEA and its business. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors which may result in a substantial divergence
between the actual results, financial situation, development or performance
of IGEA and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. IGEA assumes no responsibility to update
forward-looking statements or to adapt them to future events or
developments, except as may be required by law.


End of ad hoc announcement